SCH-900475
Showing 1 - 25 of 319
Non-small Cell Lung Carcinoma Trial (Pembrolizumab, Paclitaxel, Carboplatin)
Completed
- Non-small Cell Lung Carcinoma
- Pembrolizumab
- +7 more
- (no location specified)
Oct 13, 2022
Papillary Renal Cell Carcinoma Trial (Pembrolizumab, Placebo)
Not yet recruiting
- Papillary Renal Cell Carcinoma
- Pembrolizumab
- Placebo
- (no location specified)
Nov 24, 2023
Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Houston (other, biological, procedure)
Active, not recruiting
- Recurrent Glioblastoma
- Recurrent Gliosarcoma
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 19, 2022
Cancer of Head and Neck, Head Neck Cancer, Tumors, Head and Neck Trial in Boston, Saint Louis, New York (biological, procedure,
Active, not recruiting
- Cancer of Head and Neck
- +5 more
- MK-3475 (neoadjuvant)
- +6 more
-
Boston, Massachusetts
- +2 more
Dec 9, 2022
Lung Non-Small Cell Carcinoma Trial in Buffalo (Pembrolizumab)
Active, not recruiting
- Lung Non-Small Cell Carcinoma
- Pembrolizumab
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 27, 2023
Recurrent Glioblastoma Trial in Houston (Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab)
Not yet recruiting
- Recurrent Glioblastoma
- Pembrolizumab
- Exablate MRgFUS + neoadjuvant pembolizumab
-
Houston, TexasM D Anderson Cancer Center
May 18, 2023
Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker
Active, not recruiting
- Follicular Lymphoma
- +2 more
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 6, 2022
Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Houston
Terminated
- Locally Advanced Malignant Solid Neoplasm
- +2 more
- Pembrolizumab
- Pevonedistat
-
Houston, TexasM D Anderson Cancer Center
Dec 22, 2022
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 Trial in Chicago
Terminated
- Pancreatic Adenocarcinoma
- +2 more
- Pembrolizumab
- Wild-type Reovirus
-
Chicago, IllinoisNorthwestern University
Sep 6, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8 Trial in San Francisco (Pembrolizumab,
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Pembrolizumab
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 5, 2023
Melanoma Trial in Houston (APX005M, Pembrolizumab)
Recruiting
- Melanoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 22, 2022
Metastatic Malignant Tumor in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma Trial in
Active, not recruiting
- Metastatic Malignant Neoplasm in the Bone
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Scottsdale, ArizonaMayo Clinic in Arizona
Jan 4, 2023
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 Trial in Jacksonville (drug,
Active, not recruiting
- Metastatic Melanoma
- +3 more
- Imiquimod
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Jan 3, 2023
Colorectal Tumors, Microsatellite Instability Trial in Milano, Rozzano (temozolomide (induction),, pembrolizumab (treatment))
Recruiting
- Colorectal Neoplasms
- Microsatellite Instability
- temozolomide (induction),
- pembrolizumab (treatment)
-
Milano, Italy
- +3 more
Sep 28, 2022
Thymoma, Thymic Cancer Trial in Houston (Pembrolizumab)
Recruiting
- Stage III Thymoma AJCC v8
- +6 more
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Nov 11, 2022
Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (Azacitidine, Pembrolizumab)
Active, not recruiting
- Melanoma and Other Malignant Neoplasms of Skin
- Metastatic Melanoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Oct 31, 2022
Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)
Terminated
- Hodgkin's Lymphoma
- Pembrolizumab
- Umbralisib
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 22, 2022
Triple Negative Breast Cancer Trial in New York (Merck 3475 Pembrolizumab, Intraoperative radiation therapy (IORT))
Recruiting
- Triple Negative Breast Cancer
- Merck 3475 Pembrolizumab
- Intraoperative radiation therapy (IORT)
-
New York, New YorkColumbia University Irving Medical Center
Oct 10, 2022
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,
Active, not recruiting
- High Risk Myelodysplastic Syndrome
- +2 more
- Azacitidine
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor Trial in Houston (Alisertib, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Malignant Solid Neoplasm
- Alisertib
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Locally Advanced Malignant Solid Tumor Trial in Houston (Pembrolizumab)
Recruiting
- Locally Advanced Malignant Solid Neoplasm
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Mar 22, 2022
Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8 Trial in Houston
Active, not recruiting
- Stage I Bladder Cancer AJCC v8
- +4 more
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Oct 20, 2022
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma Trial in Seattle
Terminated
- Advanced Hepatocellular Carcinoma
- +2 more
- Cabozantinib S-malate
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 12, 2022
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial in
Recruiting
- Advanced Hepatocellular Carcinoma
- +4 more
- Futibatinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 30, 2023
Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression Trial in Portland (drug, other,
Active, not recruiting
- Castration-Resistant Prostate Carcinoma
- +4 more
- Enzalutamide
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Sep 26, 2022